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We would like to thank Prof. von Mandach and Prof. Hösli
for their interest in our study and for raising some impor-
tant points [1]. We support the efforts by SAPP to provide
guidelines on the use of drugs during pregnancy, as well as
by the Swiss Teratogen Information Service (STIS) initia-
tive, which prospectively collects information on a case ba-
sis to inform healthcare providers on drug exposure during
pregnancy in Switzerland. We are convinced that drug util-
isation studies like ours benefit such efforts by highlighting
the areas of greatest medical need in this under-investigat-
ed patient population.
Prof. von Mandach and Prof. Hösli highlight several lim-
itations of Swiss healthcare claims databases, such as the
lack of information on outpatient diagnoses (i.e., the un-
derlying indication for drug use), the lack of information
on adherence to drug therapy, as well as the the lack of in-
formation of drug dosage. As for any type of research, it
is important to consider such limitations when framing the
study question in observational database research, because
not every question can be studied in every data source.
Nevertheless, we feel strongly that the absence of such in-
formation should not prevent the use of such longitudi-
nal and representative databases, which have become an
established data source for drug utilisation studies word-
wide. Healthcare claims databases are the only available
data source in Switzerland that capture dispensed drugs
representatively for the overall population and longituti-
nally over time. It is correct that specific epilepsy preg-
nancy registries (e.g., the international EURAP or North
American NAADPR) document indications for antiseizure
medications, drug dosages, and pregnancy outcomes in the
mother and the child in much more detail than claims data-
bases. However, the populations enrolled in such registries
are highly pre-selected, because women have to actively
enroll themselves (NAADPR) or have to be enrolled by
their treating specialist/epileptologist (EURAP) [2]. Thus,
while such registries can provide excellent information on
birth outcomes and details on drug use, they cannot pro-
vide representative and population-based evidence on drug
utilisation [2]. Studies like ours have to be seen as comple-
mentary to such registry-based studies, whereby each type
of study contributes different important and valid informa-
tion to the bigger picture [2].
As Prof. von Mandach pointed out, Denmark and other
Scandinavian countries have invested in building elaborate
national birth registries to capture data on all pregnancies
in the country [3]. These registries can be linked to national
healthcare claims databases and other national health reg-
istries. Such efforts have been part of a strong national fo-
cus on public health measures in Scandinavia over decades
and are embedded in a centralised national health system.
Although desirable, a comparable birth/pregnancy registry
has not been established in Switzerland to date, and the use
of representative data to monitor drug utilisation in vulner-
able patient populations has not been promoted on an insti-
tutional level in the past. We hope that our study highlights
the benefits of using pre-existing electronic health data to
representatively evaluate drug utilisation in Switzerland,
and we hope that studies like ours support the integra-
tion of such research into national public health efforts. Of
course, it will be important to collect and analyse repre-
sentative data in a way that is compatible with the Swiss
decentralised healthcare system, which is very different
from Scandinavian healthcare systems. Helsana is one of
the largest health insurance companies in Switzerland, but
nevertheless it still “only” covers approximately 15% of
a relatively small Swiss population; therefore the sample
size is small for evaluation of rare exposures. As discussed
in the manuscript, this is the reason why we cannot provide
unweighted absolute results of our study for confidentiali-
ty reasons. A national electronic patient dossier would be
highly desirable in order to better evaluate several health
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aspects on a population-based level in Switzerland, but at
the moment, it seems unlikely that it will be implemented
in the near future. Furthermore, it will take a long time for
such an electronic dossier to achieve a large enough sam-
ple size and long enough follow up.
Finally, we would like to clarify one important point
raised. It is true that the start of pregnancy is not recorded
in healthcare claims databases, as this is not an event that is
billed to health insurers. This is a limitation that is common
to all claims databases worldwide. Nevertheless, health-
care claims databases have become an established tool to
evaluate drug use and safety during pregnancy, and estima-
tion of the last menstrual period to approximate the start
of pregnancy has been validated in several peer-reviewed
publications and is common practice in this field of re-
search [4–8]. It is correct that first trimester ultrasound is
a more exact method to determine actual gestational age,
but although health insurance reimburses this examination,
actual information on the exact gestational age determined
by the ultrasound is not recorded in health insurance data.
In theory, the claim for the examination should be indica-
tive of the 12th or 13th week of pregnancy. However, in
practice this point in time can vary, depending on factors
such as whether or not a pregnancy is considered “high-
risk” and is thus affected by larger inaccuracies. Addition-
ally, first-trimester ultrasounds are usually reimbursed as a
bundeled TARMED payment for a prenatal visit.
We thank our colleagues for their interest in our work
and we look forward to contributing evidence to benefit
pregnant women in Switzerland in synergy with efforts by
SAPP and the STIS.
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